Abstract:Cardiac arrhythmias cause significant morbidity and mortality and pose a major public health problem. They arise from disruptions in the normally orderly propagation of cardiac electrophysiological activation and recovery through successive cardiomyocytes in the heart. They reflect abnormalities in automaticity, initiation, conduction, or recovery in cardiomyocyte excitation. The latter properties are dependent on surface membrane electrophysiological mechanisms underlying the cardiac action potential. Their disruption results from spatial or temporal instabilities and heterogeneities in the generation and propagation of cellular excitation. These arise from abnormal function in their underlying surface membrane, ion channels, and transporters, as well as the interactions between them. The latter, in turn, form common regulatory targets for the hierarchical network of diverse signaling mechanisms reviewed here. In addition to direct molecular-level pharmacological or physiological actions on these surface membrane biomolecules, accessory, adhesion, signal transduction, and cytoskeletal anchoring proteins modify both their properties and localization. At the cellular level of excitation–contraction coupling processes, Ca 2+ homeostatic and phosphorylation processes affect channel activity and membrane excitability directly or through intermediate signaling. Systems -level autonomic cellular signaling exerts both acute channel and longer-term actions on channel expression. Further upstream intermediaries from metabolic changes modulate the channels both themselves and through modifying Ca 2+ homeostasis. Finally, longer-term organ -level inflammatory and structural changes, such as fibrotic and hypertrophic remodeling, similarly can influence all these physiological processes with potential pro-arrhythmic consequences. These normal physiological processes may target either individual or groups of ionic channel species and alter with particular pathological conditions. They are also potentially alterable by direct pharmacological action, or effects on longer-term targets modifying protein or cofactor structure, expression, or localization. Their participating specific biomolecules, often clarified in experimental genetically modified models, thus constitute potential therapeutic targets. The insights clarified by the physiological and pharmacological framework outlined here provide a basis for a recent modernized drug classification. Together, they offer a translational framework for current drug understanding. This would facilitate future mechanistically directed therapeutic advances, for which a number of examples are considered here. The latter are potentially useful for treating cardiac, in particular arrhythmic, disease.

Pharmacotherapy in inherited and acquired ventricular arrhythmia in structurally normal adult hearts

Ventricular Arrhythmias in Ischemic Cardiomyopathy—New Avenues for Mechanism-Guided Treatment

Mechanistic and Therapeutic Perspectives for Cardiac Arrhythmias: Beyond Ion Channels

Pharmacotherapy of cardiac arrhythmias--basic science for clinicians.

Pharmacotherapy in Ventricular Arrhythmias

Pharmacotherapy of Cardiac Arrhythmias—Basic Science for Clinicians

Inherited conditions of arrhythmia: translating disease mechanisms to patient management

Tachyarrhythmias in congenital heart disease

Gene and stem cell therapy for inherited cardiac arrhythmias

Management of ventricular tachycardia in patients with ischaemic cardiomyopathy: contemporary armamentarium

Cardiac arrhythmogenesis: roles of ion channels and their functional modification

Novel Therapeutic Strategies for the Management of Ventricular Arrhythmias Associated with the Brugada Syndrome

The proarrhythmogenic role of autonomics and emerging neuromodulation approaches to prevent sudden death in cardiac ion channelopathies

When Is Less More?

Update on management of cardiac arrhythmias in acute coronary syndromes

The Brugada syndrome: pharmacological therapy

Sarcoplasmic Reticulum Ca2+ Dysregulation in the Pathophysiology of Inherited Arrhythmia: an Update

[Cardiac channelopathies in the context of hereditary arrhythmia syndromes]

Cardiac Arrhythmias and Their Management: An In-Depth Review of Current Practices and Emerging Therapies

Pathophysiology and treatment of adults with arrhythmias in the emergency department, part 1: Atrial arrhythmias

Precision Medicine in Catecholaminergic Polymorphic Ventricular Tachycardia: Recent Advances Toward Personalized Care